Table 3 Additional antibiotics and neutropenic fever related outcomes in management of neutropenic fever in pediatric oncology ward of TASH (N = 135)
Item description | N (%) |
|---|---|
Antiviral added | |
 Yes | 30 (22.2) |
 Acyclovir | 30 (22.2) |
 No | 105 (77.8) |
Antifungal added | |
 Yes | 52 (38.5) |
 Fluconazole | 43 (31.8) |
 Itraconazole | 1 (0.7) |
 Amphotercin B | 1 (0.7) |
 Miconazole | 7 (5.2) |
 Othera | 7 (5.2) |
 No | 83 (61.5) |
Antibacterial added | |
 Yes | 15 (11.1) |
 Ciprofloxacin | 1 (0.7) |
 Cotrimoxazole | 9 (6.7) |
 Cotrimoxazole + ciprofloxacin | 5 (3.7) |
 No | 120 (88.9) |
Antibiotic finished place | |
 In the hospital | 118 (87.4) |
 Outside of the hospital | 17 (12.6) |
ANC value after antibiotic treatment in cell/mm3 | |
 < 500 | 26 (19.3) |
 500–1000 | 33 (24.4) |
 1000–1500 | 29 (21.5) |
 > 1500 | 47 (34.8) |
Body temperature after FN treatment | |
 Afebrile | 133 (98.5) |
 Febrile | 2 (1.5) |
Outcome related to FN | |
 Treated | 95 (70.4) |
 All cause mortality | 7 (5.2) |
 Unknown status | 33 (24.4) |